MARKET

IBRX

IBRX

ImmunityBio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.37
+0.02
+0.28%
Opening 10:16 01/27 EST
OPEN
5.42
PREV CLOSE
5.35
HIGH
5.53
LOW
5.36
VOLUME
97.50K
TURNOVER
--
52 WEEK HIGH
45.42
52 WEEK LOW
5.06
MARKET CAP
2.13B
P/E (TTM)
-5.6072
1D
5D
1M
3M
1Y
5Y
Liberty One Investment Management, Llc Buys Fastly Inc, Kratos Defense & Security Solutions ...
Investment company Liberty One Investment Management, Llc (Current Portfolio) buys Fastly Inc, Kratos Defense & Security Solutions Inc, Twilio Inc, Boston Beer Co Inc, ImmunityBio Inc, sells InterDigital Inc, T-Mobile US Inc, Stericycle Inc, Cheniere Energ...
GuruFocus.com · 5d ago
ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
ImmunityBio Inc (NASDAQ: IBRX) has 
Benzinga · 01/19 14:27
ImmunityBio posts early data for Nant Cancer Vaccine in pancreatic cancer
ImmunityBio (NASDAQ:IBRX) is trading ~6.5% higher in the pre-market in reaction to the company’s announcement yesterday detailing the interim data from a Phase 2 trial for its combination immunotherapy (Nant Cancer Vaccine)
Seekingalpha · 01/19 12:49
Billionaire Soon-Shiong Launches 1 Billion-Dose Vaccine Plant in Cape Town
(Bloomberg) -- Most Read from BloombergMicrosoft Buys Scandal-Tainted Activision in Bet on MetaverseFourth Pfizer Dose Is Insufficient to Ward Off Omicron, Israeli Trial SuggestsCovid-19 Infected Lions Prompt Variant Warning in South AfricaStock Selloff De...
Bloomberg · 01/19 10:01
ImmunityBio Announces Results Of Phase 2 Metastatic Pancreatic Cancer Trial At ASCO GI With Median Overall Survival Of 6.3 Months In Patients With Third-Line Disease, More Than Doubling Historical Survival
ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate for patients
Benzinga · 01/18 23:04
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference.
Benzinga · 01/16 21:38
Inside the Athenex-ImmunityBio deal — and the California company's employment plans
A relationship that began at American Pharmaceutical Partners, which had a longtime plant on Grand Island, led the immunotherapy and cell therapy company to Dunkirk.
American City Business Journals · 01/13 14:00
ImmunityBio in pact to acquire certain assets, leasehold interest from Athenex
ImmunityBio (IBRX +3.4%) has acquired a leasehold interest in 409K sq. ft. of ISO Class 5 pharmaceutical manufacturing space in western New York, and certain related assets, from global pharmaceutical
Seekingalpha · 01/12 14:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBRX. Analyze the recent business situations of ImmunityBio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IBRX stock price target is 20.00 with a high estimate of 20.00 and a low estimate of 20.00.
High20.00
Average20.00
Low20.00
Current 5.37
EPS
Actual
Estimate
-0.33-0.25-0.16-0.08
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 169
Institutional Holdings: 33.08M
% Owned: 8.31%
Shares Outstanding: 397.80M
TypeInstitutionsShares
Increased
51
5.21M
New
21
787.47K
Decreased
26
832.60K
Sold Out
16
689.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.69%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Chief Scientific Officer/Executive Director
Patrick Soon-Shiong
President/Chief Executive Officer/Director
Richard Adcock
Chief Financial Officer
David Sachs
Senior Vice President - Finance
Sonja Nelson
Senior Vice President
Sigrid Schreiner
Other/Director
Barry Simon
Other
Helen Luu
Independent Director
Michael Blaszyk
Independent Director
John Brennan
Independent Director
Wesley Clark
Independent Director
Cheryl Cohen
Independent Director
Linda Maxwell
Independent Director
Christobel Selecky
No Data
About IBRX
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term immunological memory. The Company is engaged in developing molecular and product platforms based on three key modalities: activating NK and T cells using antibody cytokine fusion proteins, activating tumoricidal macrophages using low-dose synthetic immunomodulators, and generating memory T cells using vaccine candidates developed with second-generation adenovirus (hAd5) technology. It is also developing therapies, including vaccines, for the prevention and treatment of human immunodeficiency virus (HIV), influenza, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its human adenovirus (hAd5) vaccine technologies.

Webull offers kinds of Immunitybio Inc stock information, including NASDAQ:IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.